OBJECTIVE: To determine whether prehospital antiplatelet therapy was associated with reduced incidence of acute lung dysfunction, multiple organ failure, and mortality in blunt trauma patients. DESIGN: Secondary analysis of a cohort enrolled in the National Institute of General Medical Sciences Trauma Glue Grant database. SETTING: Multicenter study including nine U.S. level-1 trauma centers. PATIENTS: A total of 839 severely injured blunt trauma patients at risk for multiple organ failure (age > 45 yr, base deficit > 6 mEq/L or systolic blood pressure < 90 mm Hg, who received a blood transfusion). Severe/isolated head injuries were excluded. MEASUREMENTS AND MAIN RESULTS: Primary outcomes were lung dysfunction (defined as grades 2-3 by the Denver multiple organ failure score), multiple organ failure (Denver multiple organ failure score >3), and mortality. Patients were documented as on antiplatelet therapy if taking acetylsalicylic acid, clopidogrel, and/or ticlopidine. Fifteen percent were taking antiplatelet therapy prior to injury. Median injury severity score was 30 (interquartile range 22-51), mean age 61 + 0.4 yr and median RBCs volume transfused was 1700 mL (interquartile range 800-3150 mL). Overall, 63% developed lung dysfunction, 19% had multiple organ failure, and 21% died. After adjustment for age, gender, comorbidities, blood products, crystalloid/12 hrs, presence of any head injury, injury severity score, and 12 hrs base deficit > 8 mEq/L, 12 hrs RBC transfusion was associated with a significantly smaller risk of lung dysfunction and multiple organ failure among the group receiving antiplatelet therapy compared with those not receiving it (lung dysfunction p = 0.0116, multiple organ failure p = 0.0291). In addition, antiplatelet therapy had a smaller risk (albeit not significant, p = 0.06) of death for patients receiving RBC compared to those not on antiplatelet therapy after adjustment for confounders, CONCLUSIONS: Pre-injury antiplatelet therapy is associated with a decreased risk of lung dysfunction, multiple organ failure, and possibly mortality in high-risk blunt trauma patients who received blood transfusions. These findings suggest platelets have a role in organ dysfunction development and have potential therapeutic implications.
OBJECTIVE: To determine whether prehospital antiplatelet therapy was associated with reduced incidence of acute lung dysfunction, multiple organ failure, and mortality in blunt traumapatients. DESIGN: Secondary analysis of a cohort enrolled in the National Institute of General Medical Sciences Trauma Glue Grant database. SETTING: Multicenter study including nine U.S. level-1 trauma centers. PATIENTS: A total of 839 severely injured blunt traumapatients at risk for multiple organ failure (age > 45 yr, base deficit > 6 mEq/L or systolic blood pressure < 90 mm Hg, who received a blood transfusion). Severe/isolated head injuries were excluded. MEASUREMENTS AND MAIN RESULTS: Primary outcomes were lung dysfunction (defined as grades 2-3 by the Denver multiple organ failure score), multiple organ failure (Denver multiple organ failure score >3), and mortality. Patients were documented as on antiplatelet therapy if taking acetylsalicylic acid, clopidogrel, and/or ticlopidine. Fifteen percent were taking antiplatelet therapy prior to injury. Median injury severity score was 30 (interquartile range 22-51), mean age 61 + 0.4 yr and median RBCs volume transfused was 1700 mL (interquartile range 800-3150 mL). Overall, 63% developed lung dysfunction, 19% had multiple organ failure, and 21% died. After adjustment for age, gender, comorbidities, blood products, crystalloid/12 hrs, presence of any head injury, injury severity score, and 12 hrs base deficit > 8 mEq/L, 12 hrs RBC transfusion was associated with a significantly smaller risk of lung dysfunction and multiple organ failure among the group receiving antiplatelet therapy compared with those not receiving it (lung dysfunction p = 0.0116, multiple organ failure p = 0.0291). In addition, antiplatelet therapy had a smaller risk (albeit not significant, p = 0.06) of death for patients receiving RBC compared to those not on antiplatelet therapy after adjustment for confounders, CONCLUSIONS: Pre-injury antiplatelet therapy is associated with a decreased risk of lung dysfunction, multiple organ failure, and possibly mortality in high-risk blunt traumapatients who received blood transfusions. These findings suggest platelets have a role in organ dysfunction development and have potential therapeutic implications.
Authors: Ernest E Moore; Frederick A Moore; Alden H Harken; Jeffrey L Johnson; David Ciesla; Ani Banerjee Journal: Shock Date: 2005-12 Impact factor: 3.454
Authors: Frederick A Moore; Bruce A McKinley; Ernest E Moore; Avery B Nathens; Michael West; Michael B Shapiro; Paul Bankey; Bradley Freeman; Brian G Harbrecht; Jeffrey L Johnson; Joseph P Minei; Ronald V Maier Journal: J Trauma Date: 2006-07
Authors: Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann Journal: Nat Med Date: 2010-08-01 Impact factor: 53.440
Authors: Johannes Winning; Jens Neumann; Matthias Kohl; Ralf A Claus; Konrad Reinhart; Michael Bauer; Wolfgang Lösche Journal: Crit Care Med Date: 2010-01 Impact factor: 7.598
Authors: Bernd Maier; Rolf Lefering; Mark Lehnert; Helmut L Laurer; Wolf I Steudel; Edmund A Neugebauer; Ingo Marzi Journal: Shock Date: 2007-12 Impact factor: 3.454
Authors: Angela Sauaia; Ernest E Moore; Jeffrey L Johnson; David J Ciesla; Walter L Biffl; Anirban Banerjee Journal: Shock Date: 2009-05 Impact factor: 3.454
Authors: Mark R Looney; John X Nguyen; Yongmei Hu; Jessica A Van Ziffle; Clifford A Lowell; Michael A Matthay Journal: J Clin Invest Date: 2009-10-05 Impact factor: 14.808
Authors: Muhammad Asaduzzaman; Shahram Lavasani; Milladur Rahman; Su Zhang; Oscar O Braun; Bengt Jeppsson; Henrik Thorlacius Journal: Crit Care Med Date: 2009-04 Impact factor: 7.598
Authors: U Hamid; A Krasnodembskaya; M Fitzgerald; M Shyamsundar; A Kissenpfennig; C Scott; E Lefrancais; M R Looney; R Verghis; J Scott; A J Simpson; J McNamee; D F McAuley; C M O'Kane Journal: Thorax Date: 2017-01-12 Impact factor: 9.139
Authors: George Kasotakis; Nichole Starr; Erek Nelson; Bedabrata Sarkar; Peter Ashley Burke; Daniel George Remick; Ronald Gary Tompkins Journal: Eur J Trauma Emerg Surg Date: 2018-04-07 Impact factor: 3.693
Authors: George Kasotakis; Manuel D Galvan; Paw Osathanugrah; Neerav Dharia; Lauren Bufe; Zachary Breed; Joseph P Mizgerd; Daniel G Remick Journal: J Surg Res Date: 2017-07-31 Impact factor: 2.192
Authors: Brian P Walcott; Arjun Khanna; Churl-Su Kwon; H Westley Phillips; Brian V Nahed; Jean-Valery Coumans Journal: J Clin Neurosci Date: 2014-07-24 Impact factor: 1.961
Authors: Benjamin M Howard; Lucy Z Kornblith; Carolyn M Hendrickson; Brittney J Redick; Amanda S Conroy; Mary F Nelson; Rachael A Callcut; Carolyn S Calfee; Mitchell Jay Cohen Journal: J Trauma Acute Care Surg Date: 2015-04 Impact factor: 3.313
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Jeffrey N Harr; Ernest E Moore; Theresa L Chin; Arsen Ghasabyan; Eduardo Gonzalez; Max V Wohlauer; Anirban Banerjee; Christopher C Silliman; Angela Sauaia Journal: J Trauma Acute Care Surg Date: 2013-03 Impact factor: 3.313